146 related articles for article (PubMed ID: 25111818)
21. Enigmas of IDH mutations in hematology/oncology.
Heuser M; Araujo Cruz MM; Goparaju R; Chaturvedi A
Exp Hematol; 2015 Aug; 43(8):685-97. PubMed ID: 26032956
[TBL] [Abstract][Full Text] [Related]
22. The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase.
Pollard PJ; Wortham NC; Tomlinson IP
Ann Med; 2003; 35(8):632-9. PubMed ID: 14708972
[TBL] [Abstract][Full Text] [Related]
23. Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.
Guilhamon P; Eskandarpour M; Halai D; Wilson GA; Feber A; Teschendorff AE; Gomez V; Hergovich A; Tirabosco R; Fernanda Amary M; Baumhoer D; Jundt G; Ross MT; Flanagan AM; Beck S
Nat Commun; 2013; 4():2166. PubMed ID: 23863747
[TBL] [Abstract][Full Text] [Related]
24. Oncometabolites-driven tumorigenesis: From genetics to targeted therapy.
Morin A; Letouzé E; Gimenez-Roqueplo AP; Favier J
Int J Cancer; 2014 Nov; 135(10):2237-48. PubMed ID: 25124653
[TBL] [Abstract][Full Text] [Related]
25. Fumarate hydratase in cancer: A multifaceted tumour suppressor.
Schmidt C; Sciacovelli M; Frezza C
Semin Cell Dev Biol; 2020 Feb; 98():15-25. PubMed ID: 31085323
[TBL] [Abstract][Full Text] [Related]
26. Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease.
Tommasini-Ghelfi S; Murnan K; Kouri FM; Mahajan AS; May JL; Stegh AH
Sci Adv; 2019 May; 5(5):eaaw4543. PubMed ID: 31131326
[TBL] [Abstract][Full Text] [Related]
27. Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates.
Ye D; Guan KL; Xiong Y
Trends Cancer; 2018 Feb; 4(2):151-165. PubMed ID: 29458964
[TBL] [Abstract][Full Text] [Related]
28. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents.
Wang P; Wu J; Ma S; Zhang L; Yao J; Hoadley KA; Wilkerson MD; Perou CM; Guan KL; Ye D; Xiong Y
Cell Rep; 2015 Dec; 13(11):2353-2361. PubMed ID: 26686626
[TBL] [Abstract][Full Text] [Related]
29. Beyond Isocitrate Dehydrogenase Mutations: Emerging Mechanisms for the Accumulation of the Oncometabolite 2-Hydroxyglutarate.
Peng S; Chen H; Chen L; Yang G; Liu J; Cheng X; Tang Y
Chem Res Toxicol; 2022 Feb; 35(2):115-124. PubMed ID: 35018778
[TBL] [Abstract][Full Text] [Related]
30. Mitochondrial metabolic remodeling in response to genetic and environmental perturbations.
Hollinshead KE; Tennant DA
Wiley Interdiscip Rev Syst Biol Med; 2016 Jul; 8(4):272-85. PubMed ID: 27196610
[TBL] [Abstract][Full Text] [Related]
31. Mutations of FH and IDH may induce gliomagenesis by similar mechanisms.
Raghunathan A; Ida CM; Westbroek EM; Gupta S; Jenkins RB; Giannini C; Aldape KD
J Neuropathol Exp Neurol; 2022 Dec; 82(1):99-100. PubMed ID: 36367829
[No Abstract] [Full Text] [Related]
32. Genetic variants in genes of tricarboxylic acid cycle key enzymes predict postsurgical overall survival of patients with hepatocellular carcinoma.
Du X; Wan S; Chen Y; Qu P; Huang X; Yu X; Yang H; Zhang Y; Xing J
Ann Surg Oncol; 2014 Dec; 21(13):4300-7. PubMed ID: 25081338
[TBL] [Abstract][Full Text] [Related]
33. Exposure to high levels of fumarate and succinate leads to apoptotic cytotoxicity and altered global DNA methylation profiles in vitro.
Wentzel JF; Lewies A; Bronkhorst AJ; van Dyk E; du Plessis LH; Pretorius PJ
Biochimie; 2017 Apr; 135():28-34. PubMed ID: 28104508
[TBL] [Abstract][Full Text] [Related]
34. [Epigenetic alterations and biological phenomena caused by mutation in an IDH gene].
Sasaki M
Seikagaku; 2016 Jun; 88(3):287-95. PubMed ID: 27483945
[No Abstract] [Full Text] [Related]
35. Rare insights into cancer biology.
Adam J; Yang M; Soga T; Pollard PJ
Oncogene; 2014 May; 33(20):2547-56. PubMed ID: 23812428
[TBL] [Abstract][Full Text] [Related]
36. Metabolic syndromes and malignant transformation: where the twain shall meet.
Bhagwat N; Levine RL
Sci Transl Med; 2010 Oct; 2(54):54ps50. PubMed ID: 20962328
[TBL] [Abstract][Full Text] [Related]
37. TET-Mediated Hypermethylation Primes SDH-Deficient Cells for HIF2α-Driven Mesenchymal Transition.
Morin A; Goncalves J; Moog S; Castro-Vega LJ; Job S; Buffet A; Fontenille MJ; Woszczyk J; Gimenez-Roqueplo AP; Letouzé E; Favier J
Cell Rep; 2020 Mar; 30(13):4551-4566.e7. PubMed ID: 32234487
[TBL] [Abstract][Full Text] [Related]
38. Metabolic Enzymes in Sarcomagenesis: Progress Toward Biology and Therapy.
Li L; Eid JE; Paz AC; Trent JC
BioDrugs; 2017 Oct; 31(5):379-392. PubMed ID: 28840584
[TBL] [Abstract][Full Text] [Related]
39. Oncometabolites: linking altered metabolism with cancer.
Yang M; Soga T; Pollard PJ
J Clin Invest; 2013 Sep; 123(9):3652-8. PubMed ID: 23999438
[TBL] [Abstract][Full Text] [Related]
40. Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas.
Castro-Vega LJ; Buffet A; De Cubas AA; Cascón A; Menara M; Khalifa E; Amar L; Azriel S; Bourdeau I; Chabre O; Currás-Freixes M; Franco-Vidal V; Guillaud-Bataille M; Simian C; Morin A; Letón R; Gómez-Graña A; Pollard PJ; Rustin P; Robledo M; Favier J; Gimenez-Roqueplo AP
Hum Mol Genet; 2014 May; 23(9):2440-6. PubMed ID: 24334767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
